ADAG
HEALTHCAREAdagene Inc
$3.61-0.01 (-0.28%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ADAG Today?
No stock-specific AI insight has been generated for ADAG yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.30$4.75
$3.61
Fundamentals
Market Cap$239M
P/E Ratio—
EPS$-0.37
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin-2.3%
Debt / Equity—
Trading
Volume129K
Avg Volume (10D)—
Shares Outstanding66.1M
ADAG News
20 articles- Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal CancerYahoo Finance·Apr 20, 2026
- Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor TypesYahoo Finance·Apr 17, 2026
- Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory BoardYahoo Finance·Apr 14, 2026
- Incyte (INCY) Is Up 6.2% After Positive Povorcitinib Data And New Oncology Collaboration - Has The Bull Case Changed?Yahoo Finance·Apr 5, 2026
- Adagene Announces Pricing of US$70.0 Million Public Offering of ADSsYahoo Finance·Apr 2, 2026
- Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)Yahoo Finance·Apr 2, 2026
- Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of ResponseYahoo Finance·Apr 2, 2026
- Adagene Reports Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire Inc.·Apr 1, 2026
- Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CAYahoo Finance·Mar 17, 2026
- Adagene Spotlights ADG126 at Leerink, Teases New MSS Colorectal Cancer Data Update SoonMarketbeat·Mar 10, 2026
- Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference TalkMarketbeat·Feb 25, 2026
- Adagene to Participate in Two Upcoming Investor ConferencesYahoo Finance·Feb 17, 2026
- Moderna's Shares Climb 5.3% as Investors Revisit Biotech LeadersYahoo Finance·Feb 16, 2026
- Adagene Provides Business Update and 2026 ObjectivesYahoo Finance·Jan 23, 2026
- Penny Stocks To Watch In January 2026Yahoo Finance·Jan 19, 2026
- 3 Promising Penny Stocks With Market Caps Over $30MYahoo Finance·Dec 19, 2025
- FDA Grants Fast Track Designation to ADAG's Colorectal Cancer DrugYahoo Finance·Dec 17, 2025
- Sector Update: Health Care Stocks Retreat Late AfternoonYahoo Finance·Dec 16, 2025
- Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)Yahoo Finance·Dec 16, 2025
- Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® TechnologyYahoo Finance·Nov 13, 2025
All 20 articles loaded
Price Data
Open$3.70
Previous Close$3.62
Day High$3.88
Day Low$3.58
52 Week High$4.75
52 Week Low$1.30
52-Week Range
$1.30$4.75
$3.61
Fundamentals
Market Cap$239M
P/E Ratio—
EPS$-0.37
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin-2.3%
Debt / Equity—
Trading
Volume129K
Avg Volume (10D)—
Shares Outstanding66.1M
About Adagene Inc
Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—